Pacific Edge

Pacific Edge Limited is a cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for the better detection and management of cancer. The company is currently developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. As it stands Pacific Edge has four proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results for the better detection and management of urothelial cancer. These products have been extensively tested and validated in international multi-center clinical studies.

Company Details

Registered Office: Anderson Lloyd, Level 10, Otago House, Cnr Moray Place And Princes Street, Dunedin 9016

Postal Address: PO Box 56, Dunedin 9016

Telephone: +64-3-479-5800

Facsimile: n/a

Website: http://www.pacificedgedx.com

First Listed: 01/10/2003

Balance Date: 31 March

AGM: 27/07/2023

Directors and Executives

Tony Barclay

Independent Director

Chris Gallaher

Chairman

Grant Gibson

Chief Financial Officer

Mark Green

Independent Director

Anatole Masfen

Independent Director

Peter Meintjes

Chief Executive Officer

Sarah Park

Independent Director

Anna Stove

Independent Director

Bryan Williams

Independent Director

Announcements

Title	Date	Type
Q4 25 Cxbladder Volumes Rise and Key Metrics Improve	Fri, Apr 04 2025 09:48 am	GENERAL
Cxbladder Incorporated into AUA Clinical Guideline	Fri, Feb 28 2025 09:17 am	GENERAL
D&O Disclosure - G Gibson	Tue, Jan 28 2025 12:23 pm	SHINTR
Medicare LCD Effective Date Extended to 24 April 2025	Mon, Jan 27 2025 09:00 am	GENERAL
Pacific Edge Releases Quarterly Volumes for Q3 FY25	Wed, Jan 22 2025 09:11 am	GENERAL
PEB – Trading resumes at market open	Mon, Jan 13 2025 09:26 am	HALT
Novitas finalizes non-coverage determination	Mon, Jan 13 2025 09:24 am	GENERAL
Pacific Edge Limited (“PEB”) – Trading Halt of Securities	Fri, Jan 10 2025 08:56 am	HALT
Capital Change Notice - Options Issue	Fri, Dec 20 2024 03:49 pm	SECISSUE
Capital Change Notice - Lapse of Options	Fri, Dec 20 2024 03:45 pm	SECISSUE

Major Holdings Announcements

Date	Name	No. Held	%	Current
17/04/23	ANZ New Zealand Investments Limited	58,714,600	6.18	7.25
18/01/23	Harbour Asset Management Limited an	127,988,137	14.78	15.79
10/12/21	Salt Funds Management Limited	48,114,089	6.95	5.94
30/09/21	Westpac Banking Corporation	52,810,384	8.14	6.70
03/12/20	AMP Capital Investors (New Zealand)	36,125,581	5.16	4.98
03/12/18	Jarden Partners Limited.	83,613,923	15.60	17.61
06/06/18	BNP Paribas Nominees (NZ) Limited a	20,612,121	5.47	4.42
05/07/17	Investment Services Group Limited	19,015,596	5.94	4.76
05/07/17	Devon Funds Management Limited	19,015,596	5.94	4.76
28/06/17	Harbour Asset Management & Jarden P	48,540,480	11.11	12.14
17/02/17	K One W One Limited	19,786,297	5.39	4.96
07/11/16	Superlife Trustee Nominees Limited,	2,033,501	5.99	0.53

Director’s Interests Announcements

Date	Name	No. Held	%	Details	Other
21/12/22	Peter Meintjes	185,000	-	-	-
22/03/22	Antony George Barclay	20,000	-	-	-
09/12/21	Bryan Williams	237,427	-	-	-
22/10/21	David Gregory Darling	4,611,562	-	-	-
22/10/21	Grant Edward Gibson	27,456	-	-	-
20/10/21	Sarah Park	58,591	-	-	-
06/10/21	Chris Gallaher	602,058	-	-	-
16/03/21	Anna Kate Stove	5,000	-	-	-
19/12/19	Kate Elizabeth Rankin	1,775,890	-	-	-
16/08/19	James Miller Suttie	190,568	-	-	-
30/05/19	John Duncan	900,333	-	-	-
30/06/16	Christopher John Swann	1,171,641	0.37	-	-

Analysts’ Forecasts

No forecasts available

Disclaimer

Data on this page is from BusinessDesk and NZX Ltd for information purposes only. Details are believed to be accurate but no warranty is given as to accuracy, timeliness, reliability or completeness. No person should rely on the contents of the report and all persons should obtain independent professional advice before acting on any information connected with or contained in this report.

Last Updated: 08/06/2023